SMAD4 and pancreatic neoplasm: SMAD4 loss was associated with shorter OS (18.3 months versus 30.1 months for preserved SMAD4; p < 0.001) and disease-free survival (DFS) (6.0 months versus 13.5 months for preserved SMAD4; p < 0.001) in patients with resectable pancreatic cancer [69].